Clinical Trial Search

Primary: Number of Participants to Develop Essential Fatty Acid Deficiency (EFAD) Defined by Holman Index > 0.4 — 0; 0 Participants

Primary: Mean Change in the TH17 Cell Cytokine IL-17 Secretion in Response to T-cell Differentiation — -176.9; -7.2 pg/mL — p=0.01

Primary: Lens Fit Acceptance Rating — 3.28; 3.48 score on a scale

Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient

Primary: Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months — 30.5 Percentage of participants — p=<0.0001

Primary: Responder Rate for Décolleté Wrinkles According to the Merz Aesthetics Scale (MAS)-At Rest Scale as Assessed by the Blinded Live Rater — 71.8; 83.7; 73.5 percentage of…

Primary: Penetration (Rate of Referral to TUTS or Medication Prescription) — 66; 180; 40; 222 Participants

Primary: Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39 — 7.4; 7.9; 7.8; 10.2 pmol/l

Primary: Reduction in Leaflet Motion — 12 Participants

Primary: Number of Participants Assessed for Relative Change in the Index of Microcirculatory Resistance Before and After Ranolazine Therapy — 7 Participants

Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0.0; 50.0; 0.0; 0.0 percentage of participants

Primary: Overall Survival (OS) — 14.1; 9.9 Months

Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale

Primary: The Number of Participants With a Serological Response by Month 6. — 94; 87 Participants — p=0.002

Primary: Overall Survival (OS) — 10.78; 7.46 months — p=< 0.001